In the context of increasing resistance to conventional antibiotics, ongoing research in this area seeks to leverage the distinctive properties of AMPs to provide effective alternatives for the control of intestinal infections.[15] On the other hand, AMPs are unstable in biological systems when administered orally, as they pass through the GIT.[16, 17] Many of the enzymes present in the GIT can hydrolyze or denature AMPs, preventing these molecules from fully reaching the intestinal tract and reducing the ideal treatment concentration to combat pathogenic bacteria in the microbiota.[18]. This evidence concerns the gene ADSL and digestive system infectious disorder.